Advertisement

Prediction of Prostate Cancer Risk Among Men Undergoing Combined MRI-targeted and Systematic Biopsy Using Novel Pre-biopsy Nomograms That Incorporate MRI Findings

Published:November 16, 2017DOI:https://doi.org/10.1016/j.urology.2017.09.035

      Objective

      To develop nomograms that predict the probability of overall prostate cancer (PCa) and clinically significant PCa (Gleason ≥7) on magnetic resonance imaging (MRI)-targeted, and combined MRI-targeted and systematic, prostate biopsy.

      Materials and Methods

      From June 2012 to August 2014, magnetic resonance imaging to ultrasound fusion-targeted prostate biopsy was performed on 464 men with suspicious regions identified on pre-biopsy 3T MRI along with systematic 12 core biopsy. Logistic regression modeling was used to evaluate predictors of overall and clinically significant PCa, and corresponding nomograms were generated for men who were not previously biopsied or had 1 or more prior negative biopsies. Models were created with 70% of a randomly selected training sample and bias-corrected using bootstrap resampling. The models were then validated with the remaining 30% testing sample pool.

      Results

      A total of 459 patients were included for analysis (median age 66 years, prostate-specific antigen [PSA] 5.2 ng/mL, prostate volume 49 cc). Independent predictors of PCa on targeted and systematic prostate biopsy were PSA density, age, and MRI suspicion score. PCa probability nomograms were generated for each cohort using the predictors. Bias-corrected areas under the receiver-operating characteristic curves for overall and clinically significant PCa detection were 0.82 (0.78) and 0.91 (0.84) for men without prior biopsy and 0.76 (0.65) and 0.86 (0.87) for men with a prior negative biopsy in the training (testing) samples.

      Conclusion

      PSA density, age, and MRI suspicion score predict PCa on combined MRI-targeted and systematic biopsy. Our generated nomograms demonstrate high diagnostic accuracy and may further aid in the decision to perform biopsy in men with clinical suspicion of PCa.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2015.
        CA Cancer J Clin. 2015; 65
        • Carter H.B.
        • Albertsen P.C.
        • Barry M.J.
        • et al.
        Early detection of prostate cancer: AUA Guideline.
        J Urol. 2013; 190: 419
        • Loeb S.
        • Bjurlin M.A.
        • Nicholson J.
        • et al.
        Overdiagnosis and overtreatment of prostate cancer.
        Eur Urol. 2014; 65: 1046
        • Moyer V.A.
        • Force U.S.P.S.T.
        Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.
        Ann Intern Med. 2012; 157: 120
        • Jemal A.
        • Fedewa S.A.
        • Ma J.
        • et al.
        Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations.
        JAMA. 2015; 314: 2054
        • Mendhiratta N.
        • Rosenkrantz A.B.
        • Meng X.
        • et al.
        MRI-ultrasound fusion-targeted prostate biopsy in a consecutive cohort of men with no previous biopsy: reduction of over-detection through improved risk stratification.
        J Urol. 2015; 194: 160-166
        • Meng X.
        • Rosenkrantz A.B.
        • Mendhiratta N.
        • et al.
        Relationship between prebiopsy multiparametric magnetic resonance imaging (MRI), biopsy indication, and MRI-ultrasound fusion-targeted prostate biopsy outcomes.
        Eur Urol. 2016; 69: 512-517
        • Mendhiratta N.
        • Meng X.
        • Rosenkrantz A.B.
        • et al.
        Prebiopsy MRI and MRI-ultrasound fusion-targeted prostate biopsy in men with previous negative biopsies: impact on repeat biopsy strategies.
        Urology. 2015; 86: 1192
        • Rosenkrantz A.B.
        • Scionti S.M.
        • Mendrinos S.
        • et al.
        Role of MRI in minimally invasive focal ablative therapy for prostate cancer.
        AJR Am J Roentgenol. 2011; 197: W90
        • Chun F.K.
        • Karakiewicz P.I.
        • Huland H.
        • et al.
        Role of nomograms for prostate cancer in 2007.
        World J Urol. 2007; 25
        • Salami S.S.
        • Vira M.A.
        • Turkbey B.
        • et al.
        Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer.
        Cancer. 2014; 120: 2876
        • Rosenkrantz A.B.
        • Kim S.
        • Lim R.P.
        • et al.
        Prostate cancer localization using multiparametric MR imaging: comparison of Prostate Imaging Reporting and Data System (PI-RADS) and Likert scales.
        Radiology. 2013; 269
        • Mendhiratta N.
        • Meng X.
        • Rosenkrantz A.B.
        • et al.
        Pre-biopsy MRI and MRI-ultrasound fusion-targeted prostate biopsy in men with previous negative biopsies: impact on repeat biopsy strategies.
        Urology. 2015; 86: 1192-1199
        • Wysock J.S.
        • Rosenkrantz A.B.
        • Huang W.C.
        • et al.
        A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial.
        Eur Urol. 2014; 66: 343-351
        • Wysock J.S.
        • Mendhiratta N.
        • Zattoni F.
        • et al.
        Predictive value of negative 3T multiparametric prostate MRI on 12 core biopsy results.
        BJU Int. 2016; 118: 515-520
        • Abraham N.E.
        • Mendhiratta N.
        • Taneja S.S.
        Patterns of repeat prostate biopsy in contemporary clinical practice.
        J Urol. 2015; 193: 1178
        • Weinreb J.C.
        • Barentsz J.O.
        • Choyke P.L.
        • et al.
        PI-RADS prostate imaging—reporting and data system: 2015, version 2.
        Eur Urol. 2016; 69: 16
        • Filson C.P.
        • Natarajan S.
        • Margolis D.J.
        • et al.
        Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: the role of systematic and targeted biopsies.
        Cancer. 2016; 122: 884
        • Chun F.K.
        • Karakiewicz P.I.
        • Briganti A.
        • et al.
        Prostate cancer nomograms: an update.
        Eur Urol. 2006; 50: 914
        • Dong F.
        • Kattan M.W.
        • Steyerberg E.W.
        • et al.
        Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice.
        J Urol. 2008; 180: 150
        • Kattan M.W.
        • Eastham J.A.
        • Wheeler T.M.
        • et al.
        Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors.
        J Urol. 2003; 170: 1792
        • Hansen J.
        • Auprich M.
        • Ahyai S.A.
        • et al.
        Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay.
        Eur Urol. 2013; 63: 201
        • Lopez-Corona E.
        • Ohori M.
        • Scardino P.T.
        • et al.
        A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session.
        J Urol. 2003; 170: 1184
        • Chun F.K.
        • Briganti A.
        • Graefen M.
        • et al.
        Development and external validation of an extended repeat biopsy nomogram.
        J Urol. 2007; 177: 510
        • Zaytoun O.M.
        • Kattan M.W.
        • Moussa A.S.
        • et al.
        Development of improved nomogram for prediction of outcome of initial prostate biopsy using readily available clinical information.
        Urology. 2011; 78: 392
        • Benecchi L.
        • Pieri A.M.
        • Melissari M.
        • et al.
        A novel nomogram to predict the probability of prostate cancer on repeat biopsy.
        J Urol. 2008; 180: 146
        • McKiernan J.
        • Donovan M.J.
        • O'Neill V.
        • et al.
        A novel urine exosome gene expression assay to predict high-grade prostate cancer at initial biopsy.
        JAMA Oncol. 2016; 2: 882-889
        • Rosenkrantz A.B.
        • Lepor H.
        • Huang W.C.
        • et al.
        Practical barriers to obtaining pre-biopsy prostate MRI: assessment in over 1,500 consecutive men undergoing prostate biopsy in a single urologic practice.
        Urol Int. 2016; 97: 247-248